Sign up to access all valuation multiples
Chengdu Kanghong Pharmaceutical Group Co Ltd is a pharmaceutical company. The company is engaged in the research and development, production, and sales of medicine, chemical medicine, and biological products.
1996
n/a
LTM Revenue $665M
Last FY EBITDA $210M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kanghong Pharmaceutical has a last 12-month revenue (LTM) of $665M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Kanghong Pharmaceutical achieved revenue of $620M and an EBITDA of $210M.
Kanghong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kanghong Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $665M | XXX | $620M | XXX | XXX | XXX |
| Gross Profit | $596M | XXX | $555M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $210M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 34% | XXX | XXX | XXX |
| EBIT | $208M | XXX | $178M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $182M | XXX | $166M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Kanghong Pharmaceutical's stock price is CNY 40 (or $6).
Kanghong Pharmaceutical has current market cap of CNY 37.1B (or $5.2B), and EV of CNY 31.1B (or $4.3B).
See Kanghong Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $5.2B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Kanghong Pharmaceutical has market cap of $5.2B and EV of $4.3B.
Kanghong Pharmaceutical's trades at 7.0x EV/Revenue multiple, and 20.7x EV/EBITDA.
Equity research analysts estimate Kanghong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kanghong Pharmaceutical has a P/E ratio of 28.4x.
See valuation multiples for Kanghong Pharmaceutical and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 20.7x | XXX | XXX | XXX |
| EV/EBIT | 20.8x | XXX | 24.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.4x | XXX | 31.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 24.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKanghong Pharmaceutical's last 12 month revenue growth is 11%
Kanghong Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Kanghong Pharmaceutical's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kanghong Pharmaceutical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kanghong Pharmaceutical and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 46% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kanghong Pharmaceutical acquired XXX companies to date.
Last acquisition by Kanghong Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Kanghong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Kanghong Pharmaceutical founded? | Kanghong Pharmaceutical was founded in 1996. |
| Where is Kanghong Pharmaceutical headquartered? | Kanghong Pharmaceutical is headquartered in China. |
| Is Kanghong Pharmaceutical publicy listed? | Yes, Kanghong Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Kanghong Pharmaceutical? | Kanghong Pharmaceutical trades under 002773 ticker. |
| When did Kanghong Pharmaceutical go public? | Kanghong Pharmaceutical went public in 2015. |
| Who are competitors of Kanghong Pharmaceutical? | Similar companies to Kanghong Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kanghong Pharmaceutical? | Kanghong Pharmaceutical's current market cap is $5.2B |
| What is the current revenue of Kanghong Pharmaceutical? | Kanghong Pharmaceutical's last 12 months revenue is $665M. |
| What is the current revenue growth of Kanghong Pharmaceutical? | Kanghong Pharmaceutical revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Kanghong Pharmaceutical? | Current revenue multiple of Kanghong Pharmaceutical is 6.5x. |
| Is Kanghong Pharmaceutical profitable? | Yes, Kanghong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
